Role of Gag in HIV Resistance to Protease Inhibitors
Author Information
Author(s): François Clavel, Fabrizio Mammano
Primary Institution: Inserm U941, Paris, France
Hypothesis
Gag cleavage site mutations are an important element of HIV resistance to protease inhibitors.
Conclusion
Gag cleavage site mutations play a significant role in HIV resistance to protease inhibitors and can affect viral fitness.
Supporting Evidence
- Mutations in Gag cleavage sites have been observed in both in vitro and clinical settings.
- Resistance mutations in Gag can improve viral fitness and replication capacity.
- Certain Gag mutations are frequently associated with specific protease resistance mutations.
Takeaway
HIV can become resistant to treatments called protease inhibitors, and changes in a specific part of the virus called Gag help it survive these treatments.
Methodology
The study reviews evidence from various experiments and clinical observations regarding Gag mutations and their impact on HIV resistance.
Limitations
The study primarily focuses on specific mutations and may not account for all factors influencing HIV resistance.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website